Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcturus Therapeutics Holdings (ARCT) Short-term Investments (2023 - 2025)

Arcturus Therapeutics Holdings' Short-term Investments history spans 3 years, with the latest figure at $55.0 million for Q3 2025.

  • For Q3 2025, Short-term Investments changed 0.0% year-over-year to $55.0 million; the TTM value through Sep 2025 reached $55.0 million, changed 0.0%, while the annual FY2024 figure was $55.0 million, 0.0% changed from the prior year.
  • Short-term Investments reached $55.0 million in Q3 2025 per ARCT's latest filing, roughly flat from $55.0 million in the prior quarter.
  • In the past five years, Short-term Investments ranged from a high of $55.0 million in Q4 2023 to a low of $38.5 million in Q1 2025.
  • Average Short-term Investments over 3 years is $52.9 million, with a median of $55.0 million recorded in 2023.
  • Peak YoY movement for Short-term Investments: changed 0.0% in 2024, then crashed 30.0% in 2025.
  • A 3-year view of Short-term Investments shows it stood at $55.0 million in 2023, then changed by 0.0% to $55.0 million in 2024, then changed by 0.0% to $55.0 million in 2025.
  • Per Business Quant, the three most recent readings for ARCT's Short-term Investments are $55.0 million (Q3 2025), $55.0 million (Q2 2025), and $38.5 million (Q1 2025).